Advances in immunotherapy for MMR proficient colorectal cancer

Hazel Lote; Naureen Starling; Rille Pihlak; Marco Gerlinger

doi:10.1016/j.ctrv.2022.102480

Advances in immunotherapy for MMR proficient colorectal cancer

Cancer Treat Rev. 2022 Dec:111:102480. doi: 10.1016/j.ctrv.2022.102480. Epub 2022 Nov 1.

Authors

Hazel Lote¹, Naureen Starling², Rille Pihlak³, Marco Gerlinger⁴

Affiliations

¹ The Institute of Cancer Research, London, UK; Royal Marsden Hospital, London, UK.
² Royal Marsden Hospital, London, UK.
³ Barts Cancer Institute, Queen Mary University of London, UK; Gastrointestinal Cancer Unit, St Bartholomew's Hospital, London, UK.
⁴ Barts Cancer Institute, Queen Mary University of London, UK; Gastrointestinal Cancer Unit, St Bartholomew's Hospital, London, UK. Electronic address: m.gerlinger@qmul.ac.uk.

PMID: 36335756
DOI: 10.1016/j.ctrv.2022.102480

Abstract

Survival in mismatch-repair proficient (MMRp) metastatic colorectal cancer (mCRC) remains poor and chemotherapy is the mainstay of treatment. Immunotherapy has demonstrated durable responses and a favourable side-effect profile in various cancer types and multiple clinical trials have been conducted in MMRp mCRC. In this review we summarise emerging trial data which demonstrate promising immunotherapy combinations in MMRp mCRC. We outline barriers to success, evaluate emerging biomarkers and discuss potential strategies to increase the effectiveness of immunotherapy in MMRp mCRC.

Publication types

Review

MeSH terms

Colorectal Neoplasms* / drug therapy
Colorectal Neoplasms* / pathology
DNA Mismatch Repair*
Humans
Immunotherapy